Prasanna Rajagopalan*†, Abdulrahim Hakami*†, Mohammed Ragab*, Ashraf Elbessoumy*‡
Oncology Research, Vol.27, No.8, pp. 957-964, 2019, DOI:10.3727/096504019X15555428221646
Abstract Arylidene analogs are well proven for biological activities. FCY-302, a novel small molecule belonging to
this class, was screened for its biological efficacy in leukemia and myeloma cells. FCY-302 selectively inhibited proliferation of cancer cells with GI50 values of 395.2 nM, 514.6 Nm, and 642.4 nM in HL-60, Jurkat,
and RPMI-8226 cells, respectively. The compound also increased sub-G0 peak in the cancer cell cycle and
favored apoptosis determined by annexin V assay. The compound decreased the antiapoptotic Bcl-2 levels and
increased proapoptotic Bax proteins in leukemia and myeloma cell lines. FCY-302 attenuated the mitochondrial membrane-bound Na+ More >
Login
Register
